Trastuzumab Deruxtecan

證據等級: L5

預測適應症: 1 個

Trastuzumab Deruxtecan: From HER2-Expressing Tumours to Drug-Induced Osteoporosis

One-Sentence Summary

Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (ADC) that delivers a cytotoxic topoisomerase I inhibitor (DXd) to HER2-expressing tumour cells. The TxGNN model predicts it may be effective for Drug-Induced Osteoporosis, but this direction is currently supported by 0 clinical trials and 0 publications, and the underlying rationale suggests the signal is likely a knowledge-graph artifact rather than a genuine treatment effect.

Quick Overview

Item	Content
Original Indication	Not available — `original_indications` is empty and no formal indication text is on file (data gap)
Predicted New Indication	Drug-Induced Osteoporosis
TxGNN Prediction Score	99.31%
Evidence Level	L5 (model prediction only, no supporting studies)
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (original_moa is a data gap). Based on the mechanistic notes attached to this candidate, trastuzumab deruxtecan is known to function as a HER2-targeted ADC that delivers a cytotoxic topoisomerase I inhibitor payload to HER2-expressing tumour cells — a mechanism relevant to oncology, not bone metabolism.

There is no known or literature-supported mechanism by which this drug would modulate osteoclast/osteoblast activity or bone-remodeling pathways such as RANKL/OPG. Clinically, cytotoxic chemotherapies and ADCs are far more commonly associated with drug-induced osteoporosis as a cause (a treatment side effect) rather than as a treatment for it.

Given the high TxGNN score (0.993) combined with the complete absence of clinical trials or literature, the most plausible explanation is that the knowledge graph is picking up a co-occurrence relationship between "cancer therapy drug" nodes and "chemotherapy-associated bone loss" nodes, rather than a true therapeutic signal. This prediction should be treated as biologically implausible until contradicted by new evidence.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Germany Market Information

Trastuzumab deruxtecan currently has no German market authorization on file (total_licenses = 0, market_status = 未上市 / Not marketed).

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — antibody-drug conjugate (ADC) delivering a cytotoxic topoisomerase I inhibitor payload
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Must follow cytotoxic/ADC drug handling regulations

Safety Considerations

Please refer to the package insert for safety information.

Note: A blocking data gap exists — TFDA label warnings and contraindications (DG001) have not been retrieved. This prevents any formal S1 safety pre-assessment for this candidate.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported by no clinical trials, no literature, and no plausible mechanistic link — the drug's known cytotoxic ADC mechanism is more consistent with causing bone loss than treating it. Combined with a blocking data gap on TFDA safety labeling, this candidate is not ready to advance beyond stage S0.

To proceed, the following is needed:

TFDA/BfArM package insert (warnings, contraindications) to resolve DG001
Confirmed original indication and mechanism of action (DG002)
Preclinical or mechanistic evidence linking HER2-ADC/topoisomerase I inhibition to bone metabolism pathways, if this signal is to be pursued further
Independent review to rule out knowledge-graph co-occurrence artifact before any further investment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.